Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Key PointsRegulators in the U.S. extended the review period for Exelixis’ request to approve a new cancer drug.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。